Enzo Biochem (NYSE:ENZ – Get Free Report) issued its quarterly earnings results on Monday. The medical research company reported ($0.02) earnings per share (EPS) for the quarter, Zacks reports. The firm had revenue of $7.33 million during the quarter. Enzo Biochem had a negative return on equity of 7.96% and a negative net margin of 75.34%.
Enzo Biochem Trading Up 7.2 %
NYSE:ENZ opened at $0.50 on Wednesday. The company has a fifty day moving average of $0.56 and a 200-day moving average of $0.87. Enzo Biochem has a twelve month low of $0.41 and a twelve month high of $1.30.
Wall Street Analyst Weigh In
Separately, StockNews.com began coverage on shares of Enzo Biochem in a research report on Saturday. They issued a “hold” rating on the stock.
Enzo Biochem Company Profile
Enzo Biochem, Inc develops, manufactures, and markets products and tools for clinical research, translational research, drug development, and bioscience research customers worldwide. The company offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis.
See Also
- Five stocks we like better than Enzo Biochem
- Conference Calls and Individual Investors
- 3 Hot Stock Upgrades as Analysts Look Ahead to Q2 Earnings
- Do ETFs Pay Dividends? What You Need to Know
- Arqit Stock Soars as NVIDIA’s GTC Fuels Quantum Excitement
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- 3 Must-Own Stocks to Build Wealth This Decade
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.
